Industrial Applications and Chemistry Section

Technical Meeting (TM 36930) on

Therapeutic Radiopharmaceuticals

IAEA HQ, Vienna , Austria

16 to 20 November 2009


participation form (pdf) (doc)

paper submission form (pdf) (doc)

grant application form (pdf) (doc)



Radionuclide therapy using open sources of radioisotopes in the form of radiopharmaceuticals has been in existence for nearly 60 years and started with the treatment of hyperthyroidism and differentiated thyroid cancer using Na 131 I. Bone seeking agents radiolabelled with beta emitting radionuclides such as 32 P, 89 Sr, 153 Sm and 186 Re are successfully applied for palliation of bone pain arising out of diffused metastases. In addition, several new therapeutic radiopharmaceuticals with isotopes such as 90 Y, 131 I, 177 Lu and 188 Re have been investigated and some utilized over the last decade thanks to the development of new targeting strategies using specific carrier molecules such as peptides and monoclonal antibodies. Currently, a number of clinical trials for treating primary cancer of various origins are going on at different centres around the world. The successful demonstration of the efficacy of these treatment modalities will result in large demand for therapeutic radiopharmaceuticals in the coming years. In order to meet the above demand, it is important to develop capacity for the production of therapeutic radionuclides and radiopharmaceuticals. The IAEA has been actively supporting these activities in the member states (MS). The IAEA has in the past organized several coordinated research projects (CRP) on development and preparation of therapeutic radiopharmaceuticals. Considering the large interest shown by MS and potential benefit to the patients, activities related to production of therapeutic radionuclides and radiopharmaceuticals are identified for implementation.

While there are a large number of radioisotopes proposed for targeted therapy, the practical considerations had been limiting the number of usable isotopes. The emphasis of the IAEA programs has been on therapeutic radionuclides with relatively long half life that can be made in large quantities in nuclear reactor, so that they can be transported with relative ease. Generator-produced radionuclides are another attractive option for the large scale on-site availability of therapeutic isotopes.

Biological evaluation of therapeutic radiopharmaceuticals is another important aspect in the development of therapy products in order to collect preclinical data and to obtain ethical clearance for initiating clinical trails. International collaboration would be highly beneficial in the pre-clinical evaluation and trials of new and potential products in a safe and effective manner. Towards achieving this objective, the IAEA is currently supporting a program on the Phase 1/II clinical trial of a 177 Lu-EDTMP, a new bone palliative agent that can be prepared in a cost effective manner in several countries across the world.

The objective of this Technical Meeting is to provide an expert's platform to facilitate exploring the current status and future directions to advice on most promising strategies to promote the use of therapeutic radiopharmaceuticals for the management of diseases.

The topics to be covered will include recent relevant developments in:


The meeting will consist of invited and contributed oral presentations in sessions devoted to specific topics followed by discussions. There will be restrictions on the duration and number of presentations. An electronic projector with a computer capable of reading CDs and memory sticks will be available (Power Point recommended). The official language of the meeting is English. No interpretation will be provided.


In order to participate in the meeting , the following steps must be completed:

1) Abstract Submission

Persons wishing to make a presentation must submit an abstract, maximum one page total length, in electronic format directly to The abstract must be text only and must contain the author's name, affiliation and email address. Acceptable file formats are LaTeX, Microsoft Word, HTML, or plain text. The one page abstract must be received by 05 August 2009 . The abstracts will be evaluated, and authors informed of the acceptance of their contributions by email, by 25 August 2009. The program agenda and a book of abstracts will be prepared and emailed to all participants as PDF file attachments.

Important : Contributors of material to be included in the Agency proceedings are required to assign all copyrights or rights to publish to the Agency.

2) Participation

A participant will be accepted only if the participation form is transmitted through the appropriate Governmental representative authority (Ministry of Foreign Affairs, National Atomic Energy Authority), by 5 August 2009.

Persons from IAEA Member States or invited international organizations are eligible to attend. Participants should be persons actively involved in the subject matter of the meeting. All persons wishing to participate in the work of this meeting are requested to complete a Participation Form and send it as soon as possible to the IAEA. Participants whose designations have been received by the IAEA will receive further details approximately two months before the meeting.


The presentations should be sent either as a Microsoft Word file, Power Point file, or Adobe PDF format file, complete with all text, figures and tables. All presentations will be converted as received, to an Adobe PDF file and placed on a CD-ROM for distribution to all participants at the meeting.


No registration fee is charged to participants. As a general rule, the IAEA does not pay for participants' travel and living expenses. However, limited financial support is available to assist the attendance of selected experts, principally those from developing Member States. Usually only one grant for financial support is awarded per Member State . If participants or governments wish to apply for a grant on behalf of one of their participants, they should ensure that applications for grants are:

Applications that do not comply with these requirements will not be considered. The grants awarded will be in the form of lump sums usually covering only part of the cost of attendance and normally not more than one grant per country will be provided. The grants are paid at the meeting. Financial support will be announced in early September 2009.


Designated participants who require a visa to enter Austria should submit the necessary application to the nearest diplomatic or consular representative of Austria as soon as possible. A letter of invitation, if needed, has to be requested from the Scientific Secretary.


It is the responsibility of the participants to arrange their accommodation. However, we have made provisional reservations at the Hotel Capri at the special rate of € 68 per night per room, including all taxes and breakfast buffet. Should you wish to confirm this reservation, please contact, please contact Mr Enrique Nacif ( by 5th October 2009 at the latest.

Useful information for participants in meetings at IAEA HQ in Vienna (how to reach the VIC, how to reach the airport, how to register on first day of the meeting, etc.) can be found on the web under .



Mr M.R.A. Pillai

Industrial Application and Chemistry Section
International Atomic Energy Agency
Wagramer Strasse 5, P.O. Box 100, A1400 Vienna, Austria
Tel.: +43 1 2600-21746, Fax: +43 1 26007-21746

Mr John J. Zaknun

Nuclear Medicine Section
International Atomic Energy Agency
Wagramer Strasse 5, P.O. Box 100, A1400 Vienna , Austria
Email :
Tel.: +43 1 2600-21673, Fax: +43 1 26007-21671

Mr Stig Palm

Dosimetry and Medical Radiation Physics Section
International Atomic Energy Agency
Wagramer Strasse 5, P.O. Box 100, A1400 Vienna , Austria
Email :
Tel.: +43 1 2600-21659, Fax: +43 1 26007-21659


Mr Enrique Nacif

NAPC Industrial Applications and Chemistry Section
International Atomic Energy Agency
Office A2370
Wagramer Strasse 5, P.O. Box 100, A1400 Vienna, Austria
Tel.: +43 1 2600-21747, Fax: +43 1 26007 21747

↑ top